JP2023528087A5 - - Google Patents
Info
- Publication number
- JP2023528087A5 JP2023528087A5 JP2022575399A JP2022575399A JP2023528087A5 JP 2023528087 A5 JP2023528087 A5 JP 2023528087A5 JP 2022575399 A JP2022575399 A JP 2022575399A JP 2022575399 A JP2022575399 A JP 2022575399A JP 2023528087 A5 JP2023528087 A5 JP 2023528087A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- cancer
- deficiency
- fibrosis
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008598.1A GB202008598D0 (en) | 2020-06-08 | 2020-06-08 | Novel compounds |
| GB2008598.1 | 2020-06-08 | ||
| GBGB2016758.1A GB202016758D0 (en) | 2020-10-22 | 2020-10-22 | Novel compounds |
| GB2016758.1 | 2020-10-22 | ||
| PCT/EP2021/065112 WO2021249909A1 (en) | 2020-06-08 | 2021-06-07 | 1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023528087A JP2023528087A (ja) | 2023-07-03 |
| JP2023528087A5 true JP2023528087A5 (enExample) | 2024-06-14 |
Family
ID=76444375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575399A Pending JP2023528087A (ja) | 2020-06-08 | 2021-06-07 | ミトコンドリア機能不全、癌、及び線維症の治療に使用されるＵＳＰ３０阻害剤としての１－（５－（２－シアノピリジン－４－イル）オキサゾール－２－カルボニル）－４－メチルヘキサヒドロピロロ［３，４－ｂ］ピロール－５（１Ｈ）－カルボニトリル |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US12655152B2 (enExample) |
| EP (1) | EP4161929B1 (enExample) |
| JP (1) | JP2023528087A (enExample) |
| KR (1) | KR20230022215A (enExample) |
| CN (1) | CN115836073B (enExample) |
| AU (1) | AU2021286831A1 (enExample) |
| BR (1) | BR112022024794A2 (enExample) |
| CA (1) | CA3186148A1 (enExample) |
| CO (1) | CO2022017233A2 (enExample) |
| DK (1) | DK4161929T3 (enExample) |
| ES (1) | ES3040433T3 (enExample) |
| FI (1) | FI4161929T3 (enExample) |
| HR (1) | HRP20250891T1 (enExample) |
| HU (1) | HUE072598T2 (enExample) |
| IL (1) | IL298785B2 (enExample) |
| LT (1) | LT4161929T (enExample) |
| MD (1) | MD4161929T2 (enExample) |
| MX (1) | MX2022015608A (enExample) |
| PL (1) | PL4161929T3 (enExample) |
| PT (1) | PT4161929T (enExample) |
| RS (1) | RS67140B1 (enExample) |
| SI (1) | SI4161929T1 (enExample) |
| SM (1) | SMT202500343T1 (enExample) |
| WO (1) | WO2021249909A1 (enExample) |
| ZA (1) | ZA202213877B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) * | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
| WO2023099561A1 (en) | 2021-12-01 | 2023-06-08 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| CN114646700B (zh) * | 2022-03-01 | 2023-10-20 | 浙江国邦药业有限公司 | 一种（s）-吡咯烷-2-甲腈盐酸盐的检测方法 |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| WO2026098667A1 (zh) * | 2024-11-11 | 2026-05-15 | 长春金赛药业有限责任公司 | Usp30抑制剂化合物、药物组合物及其制备方法和应用 |
| GB202500610D0 (en) | 2025-01-16 | 2025-03-05 | Mission Therapeutics Ltd | Novel compounds |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| JP2003530384A (ja) | 2000-04-06 | 2003-10-14 | メルク フロスト カナダ アンド カンパニー | カテプシンシステインプロテアーゼ阻害薬 |
| AU2003263393A1 (en) | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007119214A2 (en) | 2006-04-13 | 2007-10-25 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| UY31771A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| UY31770A1 (es) | 2008-04-18 | 2009-09-30 | Inhibidores de catepsina c | |
| UA105005C2 (uk) | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| CA2741666C (en) | 2008-10-31 | 2017-04-11 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
| US8946231B2 (en) | 2009-03-23 | 2015-02-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| JP5852658B2 (ja) | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| TW201524952A (zh) | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| JP6612751B2 (ja) | 2013-07-31 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋの阻害剤としてのピリジン、ピリミジン及びピラジンならびにその使用 |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| WO2016021629A1 (ja) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| LT3277677T (lt) * | 2015-03-30 | 2021-05-25 | Mission Therapeutics Limited | 1-ciano-pirolidino junginiai kaip usp30 inhibitoriai |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| MA43753A (fr) * | 2016-03-24 | 2018-11-28 | Mission Therapeutics Ltd | Dérivés 1-cyano-pyrrolidine comme inhibiteurs de dbu |
| ES2850349T3 (es) | 2016-09-27 | 2021-08-27 | Mission Therapeutics Ltd | Derivados de cianopirrolidina con actividad como inhibidores de USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| JP7208931B2 (ja) | 2017-06-20 | 2023-01-19 | ミッション セラピューティクス リミティド | Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類 |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors |
| EP3837262B1 (en) | 2018-08-14 | 2026-06-17 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| EP4218934B1 (en) | 2018-10-05 | 2025-06-18 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| MX2022012578A (es) | 2020-04-08 | 2022-11-07 | Mission Therapeutics Ltd | N-cianopirrolidinas con actividad como inhibidores de usp30. |
| KR20230016674A (ko) | 2020-05-28 | 2023-02-02 | 미션 테라퓨틱스 엘티디 | 미토콘드리아 기능장애의 치료를 위한 usp30 억제제로서 n-(1-시아노피롤리딘-3-일)-5-(3-(트라이플루오로메틸)페닐)옥사졸-2-카복스아미드 유도체 및 상응하는 옥사다이아졸 유도체 |
| WO2021245186A1 (en) | 2020-06-04 | 2021-12-09 | Mission Therapeutics Limited | N-cyanopyrrolidines with activity as usp30 inhibitors |
| RS67140B1 (sr) * | 2020-06-08 | 2025-09-30 | Mission Therapeutics Ltd | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primenu u lečenju mitohondrijske disfunkcije, kancera i fibroze |
-
2021
- 2021-06-07 RS RS20250744A patent/RS67140B1/sr unknown
- 2021-06-07 JP JP2022575399A patent/JP2023528087A/ja active Pending
- 2021-06-07 PL PL21732212.2T patent/PL4161929T3/pl unknown
- 2021-06-07 CN CN202180040683.1A patent/CN115836073B/zh active Active
- 2021-06-07 LT LTEPPCT/EP2021/065112T patent/LT4161929T/lt unknown
- 2021-06-07 MD MDE20230409T patent/MD4161929T2/ro unknown
- 2021-06-07 KR KR1020237000509A patent/KR20230022215A/ko active Pending
- 2021-06-07 HU HUE21732212A patent/HUE072598T2/hu unknown
- 2021-06-07 US US18/008,352 patent/US12655152B2/en active Active
- 2021-06-07 MX MX2022015608A patent/MX2022015608A/es unknown
- 2021-06-07 EP EP21732212.2A patent/EP4161929B1/en active Active
- 2021-06-07 CA CA3186148A patent/CA3186148A1/en active Pending
- 2021-06-07 BR BR112022024794A patent/BR112022024794A2/pt unknown
- 2021-06-07 IL IL298785A patent/IL298785B2/en unknown
- 2021-06-07 SI SI202130328T patent/SI4161929T1/sl unknown
- 2021-06-07 ES ES21732212T patent/ES3040433T3/es active Active
- 2021-06-07 FI FIEP21732212.2T patent/FI4161929T3/fi active
- 2021-06-07 SM SM20250343T patent/SMT202500343T1/it unknown
- 2021-06-07 PT PT217322122T patent/PT4161929T/pt unknown
- 2021-06-07 DK DK21732212.2T patent/DK4161929T3/da active
- 2021-06-07 WO PCT/EP2021/065112 patent/WO2021249909A1/en not_active Ceased
- 2021-06-07 AU AU2021286831A patent/AU2021286831A1/en active Pending
- 2021-06-07 HR HRP20250891TT patent/HRP20250891T1/hr unknown
-
2022
- 2022-11-30 CO CONC2022/0017233A patent/CO2022017233A2/es unknown
- 2022-12-21 ZA ZA2022/13877A patent/ZA202213877B/en unknown
-
2026
- 2026-01-13 US US19/447,329 patent/US20260138984A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546717A5 (enExample) | ||
| JP2023527025A5 (enExample) | ||
| HRP20250891T1 (hr) | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze | |
| JP2023520727A5 (enExample) | ||
| JP2023529570A5 (enExample) | ||
| TWI249531B (en) | Pharmaceutical compositions for treating or preventing HCV | |
| AP813A (en) | Urea derivatives as inhibitors of IMPDH enzyme. | |
| JP2019533659A5 (enExample) | ||
| BE1011980A5 (fr) | Traitement du cancer avec des epothilones. | |
| JP6577623B2 (ja) | グルタミナーゼのヘテロ環式阻害剤 | |
| JP2020524166A5 (enExample) | ||
| JP2019532950A5 (enExample) | ||
| JP2019532945A5 (enExample) | ||
| ES2364959T3 (es) | Agentes antibacterianos. | |
| JP2012524055A5 (enExample) | ||
| JP2024544660A5 (enExample) | ||
| CA2929646A1 (en) | Treatment of cardiac remodeling and other heart conditions | |
| JP2016502981A5 (enExample) | ||
| KR20190070946A (ko) | 바시트라신-알기네이트 올리고머 콘주게이트 | |
| KR20190072579A (ko) | 폴리믹신-알기네이트 올리고머 콘주게이트 | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| US20250120926A1 (en) | Pharmaceutical Composition for Preventing or Treating Cancer, Comprising Gossypol, Phenformin, and Anticancer Agent | |
| JP2022068371A (ja) | ＲＮＡｉ分子とＮ－アセチル化キトサンとを含む複合体 | |
| WO2025019815A3 (en) | Enhanced delivery epinephrine and prodrug compositions | |
| ITMI20131906A1 (it) | Composizioni solide orali a lento rilascio |